Senate Questions Health Care Firm for Profiting Off Program Meant for Poor

February 13, 2026 - 01:08

A federal program designed to help hospitals afford medications for low-income and uninsured patients is under scrutiny, with a Texas-based company at the center of a Senate investigation. Lawmakers are questioning whether the firm has exploited the program for excessive corporate gain.

The 340B program allows qualifying hospitals and clinics to purchase outpatient drugs at significant discounts. The intent is to stretch scarce federal resources, enabling these providers to offer more comprehensive care to vulnerable populations. However, critics allege that certain contract pharmacies and intermediaries have distorted the program's mission.

The Senate committee is focusing on how this company, by acting as a middleman, may be capturing a large portion of the discounts meant for safety-net hospitals. This practice, investigators suggest, inflates costs for insurers and patients while generating substantial revenue. The concern is that the financial model prioritizes profit over the program's original goal of supporting care for the poor.

The inquiry seeks detailed information on the company's operations and revenue. This hearing highlights a growing national debate over the oversight and future of the 340B program, which has expanded dramatically in recent years but faces persistent questions about whether its benefits are consistently reaching the patients it was created to serve.